Adjuvant Bisphosphonates for Breast Cancer
Name of the Trial
Why This Trial Is Important
Drugs called bisphosphonates have been shown to slow the progression of bone metastases and reduce skeletal complications in women with metastatic breast cancer. Bisphosphonates may also prevent the development of bone metastases in newly diagnosed patients with no evidence of metastasis.
"Breast cancer cells stimulate bone cells called osteoclasts, and these osteoclasts in turn stimulate the growth of breast cancer cells," said Dr. Gralow. "A bisphosphonate called clodronate has been shown to interrupt the relationship between osteoclasts and breast cancer cells in early-stage breast cancer. With this trial, we're comparing clodronate with two newer, more potent bisphosphonates - zoledronate and ibandronate.
"If we can eliminate bone as a safe harbor for breast cancer cells in women who would have experienced bone metastases as the first site of metastasis, we may be able to prevent the spread of breast cancer in these women altogether and save lives. Additionally, we hope to determine which types of breast cancer preferentially metastasize to bone," Dr. Gralow added.
Who Can Join This Trial
Study Sites and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.